TriangleNCT00145704 · REGISTRY CONDITION SEARCH
Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density
Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.
- Phase
- NA
- Status at capture
- TERMINATED
- Registry last update
- 2013-04-08
The purpose of this project is to evaluate the hypothesis that bisphosphonate treatment given to growth hormone deficient patients (regardless of current growth hormone replacement therapy status and without changing that status) significantly increases total body bone mineral density during an eighteen month period of treatment combined with calcium and Vitamin D when compared to calcium and Vitamin D treatment alone.
Open the original ClinicalTrials.gov record → · Download preserved record
What did the study report?
Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.
Who could take part
- eligibility Criteria
- Inclusion Criteria: * Growth hormone deficiency as a complication of treatment for pediatric malignancy * Dexa (bone densitometry)with z-scores of \< -1.0 in at least one site Exclusion Criteria: * Dexa (bone densitometry)with z-scores \< -1.0 in at least one site * Subjects \<18 years old * Pregnant or lactating patients * Any contraindication for or unwillingness to consider bisphosphonate treatment * Inability or unwillingness to undergo bone density evaluation * Other correctable causes of decreased bone mineral density
- healthy Volunteers
- false
- minimum Age
- 18 Years
- sex
- ALL
- std Ages
- ADULT
- OLDER_ADULT
Treatment arms and interventions
- arm Groups
- description
- No bisphosphonate therapy given, participants will take Vitamin D 400 IU daily for 18 months, as well as calcium carbonate 500 mg twice a day for 18 months.
- intervention Names
- Dietary Supplement: Vitamin D supplement
- Dietary Supplement: Calcium
- label
- Growth Hormone only
- type
- ACTIVE_COMPARATOR
- description
- Bisphosphonate Therapy-Risedronate 35 mg once a week for 18 months, Vitamin D 400 IU daily for 18 months and calcium carbonate 500 mg twice daily for 18 months
- intervention Names
- Drug: bisphosphonate therapy (risedronate)
- Dietary Supplement: Vitamin D supplement
- Dietary Supplement: Calcium
- label
- Growth Hormone & Bisphosphonate Therapy
- type
- EXPERIMENTAL
- interventions
- arm Group Labels
- Growth Hormone & Bisphosphonate Therapy
- description
- Bisphosphonate therapy given to patients with growth hormone deficiency
- name
- bisphosphonate therapy (risedronate)
- type
- DRUG
- arm Group Labels
- Growth Hormone & Bisphosphonate Therapy
- Growth Hormone only
- description
- Vitamin D given to patients with growth hormone deficiency
- name
- Vitamin D supplement
- other Names
- Over the counter Vitamin D 400 IU.
- type
- DIETARY_SUPPLEMENT
- arm Group Labels
- Growth Hormone & Bisphosphonate Therapy
- Growth Hormone only
- description
- calcium supplement given to patients with growth hormone deficiency
- name
- Calcium
- type
- DIETARY_SUPPLEMENT
Study design
- allocation
- RANDOMIZED
- intervention Model
- PARALLEL
- masking Info
- masking
- NONE
- primary Purpose
- TREATMENT
Enrollment
- count
- 6
- type
- ACTUAL
Registered outcome plans (not posted results)
- primary Outcomes
- description
- For those patients already on growth hormone replacement therapy, growth hormone will be administered as per standard of care, with standard dose ranges adjusted based upon IGF-1 monitoring. Those patients not currently receiving growth hormone replacement therapy will not be placed on therapy as a part of this study. Patients on and off growth hormone replacement therapy will be randomized in a block design to the two treatment arms to assure equal numbers in each treatment arm. The bisphosphonate to be utilized will be provided to the Arm II patients at no charge. All Arm II patients will receive the same bisphosphonate regimen, Risedronate 35 mg per oral once weekly for 18 months. All patients on arms I and II will also receive Vitamin D (400 IU p.o. daily) and calcium carbonate (500 mg p.o. twice daily) free of charge for eighteen months.
- measure
- Change in Total Body Bone Mineral Density During an 18 Month Period
- time Frame
- 18 months
Full study description
- brief Summary
- The purpose of this project is to evaluate the hypothesis that bisphosphonate treatment given to growth hormone deficient patients (regardless of current growth hormone replacement therapy status and without changing that status) significantly increases total body bone mineral density during an eighteen month period of treatment combined with calcium and Vitamin D when compared to calcium and Vitamin D treatment alone.
- detailed Description
- Adult patients with Dexa scan (bone scan) z-scores \< -1.0 (meaning low bone density) in at least one site will be selected for randomization. All patients who qualify for randomization will undergo baseline bloodwork for serum bone specific alkaline phosphatase (BSAP) and n-terminal telopeptides of collagen (NTX) levels. Recent bloodwork obtained as part of their ongoing long-term Pediatric Oncology and/or Endocrine clinic follow-up evaluation will be reviewed to exclude any baseline correctable confounding causes of osteopenia (low bone density). All women of childbearing potential will have a pregnancy test. For those patients already on growth hormone replacement therapy, growth hormone will be administered as per standard of care, with standard dose ranges adjusted based upon IGF-1(Insulin like growth factor) monitoring. Those patients not currently receiving growth hormone replacement therapy will not be placed on therapy as a part of this study. Patients on and off growth hormone replacement therapy will be randomized in a block design to the two treatment arms to assure equal numbers in each treatment arm. The bisphosphonate to be utilized will be provided to the Arm II patients at no charge. All Arm II patients will receive the same bisphosphonate regimen, Risedronate 35 mg per oral once weekly for 18 months. All patients on arms I and II will also receive Vitamin D (400 IU p.o. daily) and calcium carbonate (500 mg p.o. twice daily) free of charge for eighteen months.
Source references
Source notices and limitations
Discovery and provenance
- release id
- ctgov-registry-1336d216cbd1bbff780dac70
- edge id
- nct-edge-2ba7638ea9fc83e2a77e
- requested nct id
- NCT00145704
- primary nct id
- NCT00145704
- source kind
- ctgov_condition_query
- source record id
- Source null
- source file sha256
- 3ef78ce4ecba793eb2b9932bd51babe9d6d7cee15aba0d82d9e98002353b720a
- payload sha256
- a836eedc10ba0dd5e2f6523e40a9fa4a63d6320c18f02cdaa545c0c80ba3cae2
- payload
- clinical indication matching status
- condition_index_match_asserted_by_registry_not_reviewed
- end exclusive
- true
- id
- nct-edge-2ba7638ea9fc83e2a77e
- link basis
- returned_by_explicit_condition_and_posted_results_filter_query
- nct id
- NCT00145704
- occurrences
- context exact
- NCT00145704
- end
- 11
- exact text
- NCT00145704
- start
- 0
- offset unit
- unicode_code_points
- query cond
- Pituitary Tumors
- query disease state id
- ds-pituitary-tumors
- source file
- /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-pituitary-tumors-000.json
- source file sha256
- 3ef78ce4ecba793eb2b9932bd51babe9d6d7cee15aba0d82d9e98002353b720a
- source json pointer
- /studies/14/protocolSection/identificationModule/nctId
- source kind
- ctgov_condition_query
- source record id
- Source null
- source string basis
- parsed_JSON_string_unmodified
- source string sha256
- 6e36969285be085fd3c45c6aa24a103da6385d04678d7f51de0af34546709c2a
Preserved source evidence · Not medical advice